Core Insights - CervoMed Inc. is advancing its neflamapimod development program for dementia with Lewy bodies (DLB), with key data expected in Q1 2025 from the open-label extension phase of the RewinD-LB trial [1][3] - The company believes neflamapimod may have therapeutic potential for DLB, based on clinical and safety data from the double-blind phase of the study [3][5] - DLB affects approximately 700,000 individuals in both the U.S. and the European Union, and there are currently no FDA or EMA approved treatments for this condition [4] Company Overview - CervoMed Inc. is a clinical-stage company focused on developing treatments for age-related neurologic disorders, specifically targeting synaptic dysfunction [8] - Neflamapimod is an investigational drug designed to inhibit the alpha isoform of p38MAP kinase, with previous studies indicating its potential to improve dementia severity and cognitive function in early-stage DLB patients [6][8] Clinical Trial Details - The RewinD-LB trial is a randomized, 16-week, double-blind, placebo-controlled study involving 159 early-stage DLB participants, with primary and secondary endpoints focused on cognitive and motor functions [7] - The trial is funded by a $21.3 million grant from the National Institutes of Health's National Institute on Aging, with data from the first 16 weeks of the open-label extension phase expected in Q1 2025 [7] Pharmacokinetic Findings - Recent pharmacokinetic data from a food-effect study in healthy volunteers indicates that newer capsules of neflamapimod achieved targeted mean plasma concentrations [1][5] - A within-subject comparison showed that participants receiving the newer batch of capsules achieved better plasma concentrations compared to those who received older capsules during the double-blind phase [1][5]
CervoMed Provides Update on Neflamapimod DLB Program as Part of Presentation at the 8th International Lewy Body Dementia Conference